Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

Open access
Tang, Yanna, Fang, Wenfeng, Zhang, Yaxiong, Hong, Shaodong, Kang, Shiyang, Yan, Yue, Chen, Nan, Zhan, Jianhua, He, Xiaobo, Qin, Tao, Li, Ge, Tang, Wenyi, Peng, Peijian, Zhang, Li · 2015 · Oncotarget

Abstract

// Yanna Tang 1,2,3 ,* , Wenfeng Fang 1,2,3 ,* , Yaxiong Zhang 1,2,3 ,* , Shaodong Hong 1,2,3 , Shiyang Kang 1,2,3 , Yue Yan 1,2,3 , Nan Chen 1,2,3 , Jianhua Zhan 1,2,3 , Xiaobo He 1,2,3 , Tao Qin 1,2,3 , Ge Li 4 , Wenyi Tang 5 , Peijian Peng 5 and Li Zhang 1,2,3 1 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China 2 State Key Laboratory of Oncology in South China, Guangzhou, China 3 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 4 Key Laboratory for Stem Cells and Tissue Engineering, Sun Yat-sen University, Guangzhou, China 5 Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhu Hai, China * These authors have contributed equally to this work Correspondence to: Li Zhang, email: // Peijian Peng, email: // Keywords : NSCLC, PD-L1, EGFR status, TKI, prognosis Received : January 08, 2015 Accepted : March 01, 2015 Published : March 29, 2015 Abstract Backgrounds: Recent clinical trials have shown that immune-checkpoint blockade yields remarkable response in a subset of non–small cell lung cancer (NSCLC) patients. However, few studies directly focus on the association between epidermal growth factor receptor (EGFR) mutational status and programmed cell death-ligand 1 (PD-L1) expression. We examined whether PD-L1 is related to clinicopathologic factors and prognosis in patients with advanced NSCLC treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Methods: One-hundred and seventy patients with advanced NSCLC were explored. Paraffin-embedded tumour sections were stained with PD-L1 antibody. EGFR mutation was examined by fluorescent quantitative polymerase chain reaction (PCR). The correlations between PD-L1 expression and EGFR status and survival parameters were analyzed. Results: The overall frequency of PD-L1 over-expression was 65.9% (112/170). In lung adenocarcinoma, PD-L1 tended to be associated with mutant EGFR (PD-L1 overexpression in mutant and wild-type EGFR, 64/89 (71.9%) vs. 32/56 (57.1%), respectively; p=0.067). Subgroup analyses showed that high PD-L1 expression was associated with significantly shorter overall survival (OS) in EGFR wild-type patients (p=0.029) but not in EGFR mutant patients (p=0.932) treated with EGFR-TKIs. Even more, for EGFR mutant patients, higher expression of PD-L1 might only signal better outcome with TKIs. Conclusions: High PD-L1 expression was likely to be associated with the presence of EGFR mutation in advanced lung adenocarcinoma. For EGFR wild-type patients, the PD-L1 over expression can be considered as a poor prognostic indicator of OS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3694

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 243

Metadata

Authors
Tang, Y., Fang, W., Zhang, Y., Hong, S., Kang, S., Yan, Y., Chen, N., Zhan, J., He, X., Qin, T., Li, G., Tang, W., Peng, P., & Zhang, L.
Venue
Oncotarget
Published
2015-03-29
Volume
6
Issue
16
Pages
14209-14219
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2138619415
Cited by
243
References
5
FWCI
13.52
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.